GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture

GBX2 methylation is a novel prognostic factor in prostate cancer and an independent predictor of biochemical recurrence (BCR). We identified TET2 as an upstream regulator of GBX2 and demonstrated the benefit of investigating GBX2 methylation in patients negative for intraductal carcinoma and cribriform architecture to improve BCR prediction.